Consolidated Net Revenue Up 2% Compared to Second Quarter 2018
International Net Revenue Up 21% Compared to Second Quarter 2018
UK’s NICE Provided Positive Opinion for Reimbursement of ILUVIEN® in Non-Infectious Posterior Uveitis Indication
Launched Pilot Direct-to-Patient Marketing Campaign for ILUVIEN in the U.S. for diabetic macular edema (DME)
ATLANTA (July 29, 2019) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the quarter ended June 30, 2019. Alimera will host a conference call on Tuesday, July 30, 2019 at 9:00 AM ET to review these financial results and provide an update on corporate developments.
“During the second quarter we continued to advance our business strategy in many areas, including obtaining a positive outcome from NICE for non-infectious posterior uveitis and launching our direct-to-patient pilot campaign,” said Rick Eiswirth, president and CEO of Alimera. “Although we were disappointed in the consolidated net revenue this quarter, we are pleased with our international segment growth year over year. Our U.S. sales were impacted by greater than expected turnover in our sales force due to several new ophthalmic product launches by other companies in the first half of the year. We aggressively addressed this issue during the quarter and were fully staffed by early July.”
ILUVIEN showed a strong performance in markets outside the U.S., with international segment sales up 21% compared to the same period last year. International geographic expansion remains a strategic focus for Alimera, with new country approvals and launches for ILUVIEN expected in the latter half of this year. Alimera had previously announced the positive outcome for NICE on June 20 and the launching of the direct-to-patient campaign on May 22.
Mr. Eiswirth added, “We are now focused on returning to growth domestically, and with the recent approval of ILUVIEN for non-infectious posterior uveitis in our European markets, as well as the second quarter launch of ILUVIEN in France, we look forward to increasing share in all markets in the second half of this year. We intend to continue pursuing our strategy to leverage our global sales infrastructure and build a leading company focused on the treatment of retinal diseases.”
The following information was filed by Alimera Sciences Inc (ALIM) on Tuesday, July 30, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Alimera Sciences Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed, and by Alimera Sciences Inc.
Ticker: ALIM CIK: 1267602 Form Type:10-Q Quarterly Report Accession Number: 0001267602-19-000106 Submitted to the SEC: Tue Aug 06 2019 12:31:56 PM EST Accepted by the SEC: Tue Aug 06 2019 Period: Sunday, June 30, 2019 Industry: Pharmaceutical Preparations